Sarepta to collaborate with Genethon on DMD gene therapy; Chinese investors pull back on Pluristem investment
→ Cambridge, MA-based Sarepta $SRPT is doubling down on new work focused on developing a gene therapy for Duchenne muscular dystrophy. The biotech inked a deal to collaborate with the nonprofit Genethon, which has been working on animal models of the disease. “Our agreement with Genethon strengthens our ongoing commitment to patients and is aligned with our strategy of building the industry’s most comprehensive franchise in DMD,” stated Edward Kaye, Sarepta’s chief executive officer.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters